9 research outputs found

    Orbital Fluctuation-Induced Triplet Superconductivity : Mechanism of Superconductivity in Sr2RuO4{\rm Sr}_{2}{\rm RuO}_{4}

    Full text link
    The mechanism of superconductivity in Sr2RuO4{\rm Sr}_{2}{\rm RuO}_{4} is studied using a degenerate Hubbard model within the weak coupling theory. When the system approaches the orbital instability which is realized due to increasing the on-site Coulomb interaction between the electrons in the different orbitals, it is shown that the triplet superconductivity appears. This superconducting mechanism is only available in orbitally degenerate systems with multiple Fermi surfaces.Comment: 5 pages, 4 figure

    General Relativistic Mean Field Theory for Rotating Nuclei

    Full text link
    We formulate a general relativistic mean field theory for rotating nuclei starting from the special relativistic σω\sigma - \omega model Lagrangian. The tetrad formalism is adopted to generalize the model to the accelerated frame.Comment: 13 pages, REVTeX, no figures, submitted to Phys. Rev. Lett., the word `curved' is replaced by `non-inertial' or `accelerated' in several places to clarify the physical situation interested, some references are added, more detail discussions are given with omitting some redundant sentence

    Adenoviral p53 gene therapy for lung cancer

    Get PDF
    To determine the feasibility, safety, humoral immune response, and biological activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small cell lung cancer (NSCLC). Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled into this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 × 109 to 1 × 1011 plaque-forming units[PFU]) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response. Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing anti-adenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting ≥9 months, and 2 patients had progressive disease. Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit
    corecore